A number of existing strains of SARS-CoV-2, as well as other future variants that could arise, have the potential to escape the immune system’s cytotoxic T cell response in some portion of the population. That’s the conclusion of a new modeling study publishing February 10th in PLOS Computational Biology by Antonio Martín-Galiano of the Carlos III Health Institute, Spain, and colleagues.
Credit: Foix A et al., 2022, PLOS Computational Biology, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)
A number of existing strains of SARS-CoV-2, as well as other future variants that could arise, have the potential to escape the immune system’s cytotoxic T cell response in some portion of the population. That’s the conclusion of a new modeling study publishing February 10th in PLOS Computational Biology by Antonio Martín-Galiano of the Carlos III Health Institute, Spain, and colleagues.
The T cell response in humans is genetically encoded by HLA molecules—this means different individuals have different HLAs, programmed to recognize invading pathogens based on different parts, or “epitopes” of the pathogens. With thousands of different HLA molecules in the human population and thousands of possible epitopes in any given virus, the experimental evaluation of the immune response of every human HLA allele to every viral variant is not feasible. However, computational methods can facilitate this task.
In the new study, researchers first determined the full set of epitopes from an original reference strain of SARS-CoV-2 from Wuhan, China. The team discovered 1,222 epitopes of SARS-CoV-2 that were associated with major HLA subtypes, covering about 90% of the human population; at least 9 out of every 10 people can launch a T cell response to COVID-19 based on these 1,222 epitopes.
Then, the researchers computationally analyzed whether any of 118,000 different SARS-CoV-2 isolates from around the world, described in a National Center for Biotechnology Information (NCBI) dataset, had mutations in these epitopes. 47% of the epitopes, they showed, were mutated in at least one existing isolate. In some cases, existing isolates had mutations in multiple epitope regions, but cumulative mutations never affected more than 15% of epitopes for any given HLA allele type. When the team analyzed susceptible alleles and the geographic origin of their respective escape isolates, the team found that they co-existed in some geographical regions—including sub-Saharan Africa and East and Southeast Asia—, suggesting potential genetic pressure on the cytotoxic T cell response in these areas.
“The accumulation of these changes in independent isolates is still too low to threaten the global human population,” the authors say. “Our protocol has identified mutations that may be relevant for specific populations and warrant deeper surveillance.”
However, Martín-Galiano notes that “unnoticed SARS-CoV-2 mutations” might in future “threaten the cytotoxic T response in human subpopulations”.
############
In your coverage, please use this URL to provide access to the freely available article in PLOS Computational Biology: https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009726
Citation: Foix A, López D, Díez-Fuertes F, McConnell MJ, Martín-Galiano AJ (2022) Predicted impact of the viral mutational landscape on the cytotoxic response against SARS-CoV-2. PLoS Comput Biol 18(2): e1009726. https://doi.org/10.1371/journal.pcbi.1009726
Author Countries: United Kingdom, Spain
Funding: This research was supported by Acción Estratégica en Salud from the ISCIII (https://www.isciii.es), grants MPY 380/18 (to MJM), 388/18 (to DL) and 509/19 (to AJM-G). AJM-G is the recipient of a Miguel Servet contract by the ISCIII. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Journal
PLoS Computational Biology
DOI
10.1371/journal.pcbi.1009726
Method of Research
Computational simulation/modeling
Subject of Research
Not applicable
COI Statement
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: MJM is a founder and shareholder in the company Vaxdyn, S.L. Vaxdyn played no role in the present study. No other competing interest is declared for the remaining co-authors.